Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Infectious Disease Reports
Published in: Current Infectious Disease Reports 5/2012

01-10-2012 | Skin, Soft Tissue, Bone, and Joint Infections (N Safdar, Section Editor)

Subcutaneous Fungal Infections

Authors: Ricardo M. La Hoz, John W. Baddley

Published in: Current Infectious Disease Reports | Issue 5/2012

Login to get access

Abstract

Subcutaneous mycoses are common in tropical and subtropical regions of the world. These infections have multiple features in common, including similar epidemiology, mode of transmission, indolent chronic presentation with low potential for dissemination in immunocompetent hosts, and pyogranulomatous lesions on histopathology. Herein, we provide up-to-date epidemiologic, clinical, diagnostic, and therapeutic data for three important subcutaneous mycoses: chromoblastomycosis, mycetoma, and sporotrichosis.
Literature
1.
• Baddley JW, Dismukes WE. Chromoblastomycosis. In: Kauffman CA, Pappas PG, Sobel JD, Dismukes WE, editors. Essentials of clinical mycology. New York: Springer Press; 2011. p. 427–33. Exhaustive review of chromoblastomycosis. CrossRef
2.
Ameen M. Chromoblastomycosis: clinical presentation and management. Clin Exp Dermatol. 2009;34(8):849–54.PubMedCrossRef
3.
Howles JK, Kennedy CB, Carvin WH, et al. Chromoblastomycosis: report of nine cases from a single area in Louisiana. Arch Dermatol Syphilol. 1954;69:83–90.CrossRef
4.
Gardner JT, et al. Chromoblastomycosis in Texas: Report of four cases. Tex State J Med. 1964;60:913–7.
5.
Silva JP, de Souza W, Rozental S. Chromoblastomycosis: a retrospective study of 325 cases on Amazonic Region (Brazil). Mycopathologia. 1998-1999;143(3):171–5.CrossRef
6.
Minotto R, Verajao Bernardi CD, Mallmann, et al. Chromoblastomycosis: a review of 100 cases in the state of Rio Grande do Sul, Brazil. J Am Acad Dermatol. 2001;44:585–92.PubMedCrossRef
7.
Correia RT, Valente NY, Criado PR, et al. Chromoblastomycosis: study of 27 cases and review of medical literature. An Bras Dermatol. 2010;85(4):448–54.PubMedCrossRef
8.
Pretelt Mendoza J.: Cromomicosis. Aspectos epidemiolgicos. Analisis de 82 casos estudiados en el Centro Dermatologico “Ladislao de la Pascua” de 1956-1988. Dermatology Specialty Thesis, Universidad Nacional Autonoma de Mexico, 1989.
9.
Bonifaz A, Carrasco-Gerard E, Saúl A. Chromoblastomycosis: clinical and mycologic experience of 51 cases. Mycoses. 2001;44:1–7.PubMedCrossRef
10.
Esterre P, Andriantsimahavandy A, et al. Forty years of chromoblastomycosis in Madagascar: a review. Am J Trop Med Hyg. 1996;55:45–7.PubMed
11.
12.
Guedes Salgado C, Pereirada Silva J, Picanco Diniz JA, et al. Isolation of Fonsecaea pedrosoi from thorns of Mimosa pudica, a probable natural source of chromoblastomycosis. Rev Inst Med Trop Sao Paulo. 2004;46:33–6.
13.
Cardona-Castro N, Agudelo-Flórez P. Development of a chronic chromoblastomycosis model in immunocompetent mice. Med Mycol. 1999;37(2):81–3.PubMed
14.
Santos AL, Palmeira VF, Rozental S, et al. Biology and pathogenesis of Fonsecaea pedrosoi, the major etiologic agent of chromoblastomycosis. FEMS Microbiol Rev. 2007;31(5):570–91.PubMedCrossRef
15.
•• Salgado CG. Fungal x host interactions in Chromoblastomycosis: what we have learned from animal models and what is yet to be solved. Virulence. 2010;1(1):3–5. This review article summarizes our current understanding of the immune response against chromoblastomycosis derived from animal models. PubMedCrossRef
16.
•• Sousa MdaG, Reid DM, Schweighoffer E, et al. Restoration of pattern recognition receptor costimulation to treat chromoblastomycosis, a chronic fungal infection of the skin. Cell Host Microbe. 2011;9(5):436–43. Original article that underscores the importance of the innate immune response, pattern recognizition receptors and their potential therapeutic applications. CrossRef
17.
Rozental S, Alviano CS, de Souza W. The in vitro susceptibility of Fonsecaea pedrosoi to activated macrophages. Mycopathologia. 1994;126:85–91.PubMedCrossRef
18.
Ahrens J, Graybill JR, Abishawl A, et al. Experimental murine chromomycosis mimicking chronic progressive human disease. Am J Trop Med Hyg. 1989;40(6):651–8.PubMed
19.
de Sousa Teixeira MG, Ghosn EE, Almeida SR. Absence of CD4+ T cells impairs host defence of mice infected with Fonsecaea pedrosoi. Scand J Immunol. 2006;64:595–600.CrossRef
20.
Gimenes VMF, Sousa MG, et al. Cytokine and lymphocyte proliferation in patients with different clinical forms of chromoblasto-mycosis. Microbes Infect. 2005;7:708–13.CrossRef
21.
Queiroz-Telles F, Esterre P, Perez-Blanco M, et al. Chromoblastomycosis: an overview of clinical manifestations, diagnosis and treatment. Med Mycol. 2009;47:3–15.PubMedCrossRef
22.
McGinnis MR. Chromoblastomycosis and phaeohyphomycosis: new concepts, diagnosis and mycology. J Am Acad Dermatol. 1983;8:1–16.PubMedCrossRef
23.
Ogawa MM, Alchorne MM, Barbieri A, et al. Lymphoscintigraphic analysis in chromoblastomycosis. Int J Dermatol. 2003;42:622–5.PubMedCrossRef
24.
25.
Takase T, Baba T, Ueno K. Chromomycosis. A case with a widespread rash, lymph node metastasis and multiple subcutaneous nodules. Mycoses. 1988;31:343–52.PubMedCrossRef
26.
Wackym PA. Cutaneous chromomycosis in renal transplant recipients. Arch Intern Med. 1985;145:1036–7.PubMedCrossRef
27.
28.
Abliz P, Fukushima K, Takizawa K, et al. Specific oligonucleotide primers for identification of Cladophialophora carrionii, a causative agent of chromoblastomycosis. J Clin Microbiol. 2004;42(1):404–7.PubMedCrossRef
29.
de Andrade TS, Cury AE, de Castro LG, et al. Rapid identification of Fonsecaea by duplex polymerase chain reaction in isolates from patients with chromoblastomycosis. Diagn Microbiol Infect Dis. 2007;57(3):267–72.PubMedCrossRef
30.
Abliz P, Fukushima K, Takizawa K, et al. Rapid identification of the genus fonsecaea by PCR with specific oligonucleotide primers. J Clin Microbiol. 2003;41(2):873–6.PubMedCrossRef
31.
Bonifaz A, Paredes-Solis V, Saul A. Treating chromoblastomycosis with systemic antifungals. Expert Opin Pharmacother. 2004;5:247–54.PubMedCrossRef
32.
33.
Esterre P, Queiroz-Telles F. Management of chromoblastomycosis: novel perspectives. Curr Opin Infect Dis. 2006;19(2):148–52.PubMedCrossRef
34.
Vitale RG, Perez-Blanco M, De Hoog GS. In vitro activity of antifungal drugs against Cladophialophora species associated with human chromoblastomycosis. Med Mycol. 2009;47(1):35–40.PubMedCrossRef
35.
Caligiorne RB, Resende MA, Melillo PH, et al. In vitro susceptibility of chromoblastomycosis and phaeohyphomycosis agents to antifungal drugs. Med Mycol. 1999;37(6):405–9.PubMedCrossRef
36.
Gupta AK, Taborda PR, Sanzovo AD. Alternate week and combination itraconazole and terbinafine therapy for chromoblastomycosis caused by Fonsecaea pedrosoi in Brazil. Med Mycol. 2002;40:529–34.PubMed
37.
• Bustamante B, Campos PE. Eumycetoma. In: Kauffman CA, Pappas PG, Sobel JD, Dismukes WE, editors. Essentials of clinical mycology. 2nd ed. New York: Springer Press; 2011. p. 415–25. Extensive review of Eumycetoma.CrossRef
38.
Hospenthal DR. Agents of mycetoma. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 7th ed. Philadelphia: Churchill Livingstone; 2009. p. 3281–5.
39.
Green Jr WO, Adams TE. Mycetoma in the United States: a review and report of seven additional cases. Am J Clin Pathol. 1964;42:75–91.PubMed
40.
Bendl BJ, Mackey D, Al-Saati F, et al. Mycetoma in Saudi Arabia. J Trop Med Hyg. 1987;90(2):51–9.PubMed
41.
Develoux M, Audoin J, Treguer J, et al. Mycetoma in the Republic of Niger: clinical features and epidemiology. Am J Trop Med Hyg. 1988;38(2):386–90.PubMed
42.
Castro LG, Belda Júnior W, Salebian A, et al. Mycetoma: a retrospective study of 41 cases seen in São Paulo, Brazil, from 1978 to 1989. Mycoses. 1993;36(3–4):89–95.PubMed
43.
Khatri ML, Al-Halali HM, Fouad Khalid M, et al. Mycetoma in Yemen: clinicoepidemiologic and histopathologic study. Int J Dermatol. 2002;41(9):586–93.PubMedCrossRef
44.
Dieng MT, Sy MH, Diop BM, et al. Mycetoma: 130 cases. Ann Dermatol Venereol. 2003;130(1 Pt 1):16–9.PubMed
45.
Bakshi R, Mathur DR. Incidence and changing pattern of mycetoma in western Rajasthan. Indian J Pathol Microbiol. 2008;51(1):154–5.PubMedCrossRef
46.
Castro LG, Piquero-Casals J. Clinical and mycologic findings and therapeutic outcome of 27 mycetoma patients from São Paulo, Brazil. Int J Dermatol. 2008;47(2):160–3.PubMedCrossRef
47.
Padhi S, Uppin SG, Uppin MS, et al. Mycetoma in South India: retrospective analysis of 13 cases and description of two cases caused by unusual pathogens: Neoscytalidium dimidiatum and Aspergillus flavus. Int J Dermatol. 2010;49(11):1289–96.PubMedCrossRef
48.
Ahmed AO, van Leeuwen W, Fahal A, et al. Mycetoma caused by Madurella mycetomatis: a neglected infectious burden. Lancet Infect Dis. 2004;4(9):566–74.PubMedCrossRef
49.
van de Sande WW, Gorkink R, Simons G, et al. Genotyping of Madurella mycetomatis by selective amplification of restriction fragments (amplified fragment length polymorphism) and subtype correlation with geographical origin and lesion size. J Clin Microbiol. 2005;43(9):4349–56.PubMedCrossRef
50.
van de Sande WW, Janse DJ, Hira V, Goedhart H, et al. Translationally controlled tumor protein from Madurella mycetomatis, a marker for tumorous mycetoma progression. J Immunol. 2006;177(3):1997–2005.PubMed
51.
Mahgoub ES, Gumaa SA, El Hassan AM. Immunological status of mycetoma patients. Bull Soc Pathol Exot Filiales. 1977;70(1):48–54.PubMed
52.
Fahal AH, Sadig ME, Suliman SH, et al. Lack of association between ABO blood groups and Rh factor and the tendency to develop mycetoma. East Afr Med J. 1996;73(11):771.PubMed
53.
Fahal AH, el Toum EA, el Hassan AM, et al. The host tissue reaction to Madurella mycetomatis: new classification. J Med Vet Mycol. 1995;33:15.PubMedCrossRef
54.
van de Sande WW, Fahal A, Verbrugh H, van Belkum A. Polymorphisms in genes involved in innate immunity predispose toward mycetoma susceptibility. J Immunol. 2007;179:3065.PubMed
55.
Ameen M, Arenas R. Emerging therapeutic regimes for the management of mycetomas. Expert Opin Pharmacother. 2008;9(12):2077–85.PubMedCrossRef
56.
El Hag IA, Fahal AH, Gasim ET. Fine needle aspiration cytology of mycetoma. Acta Cytol. 1996;40(3):461–4.PubMedCrossRef
57.
Gabhane SK, Gangane N, Anshu A. Cytodiagnosis of eumycotic mycetoma: a case report. Acta Cytol. 2008;52(3):354–6.PubMedCrossRef
58.
Afroz N, Khan N, Siddiqui FA, et al. Eumycetoma versus actinomycetoma: Diagnosis on cytology. J Cytol. 2010;27(4):133–5.PubMedCrossRef
59.
Hemalata M, Prasad S, Venkatesh K, et al. Cytological diagnosis of actinomycosis and eumycetoma: a report of two cases. Diagn Cytopathol. 2010;38(12):918–20.PubMedCrossRef
60.
• Yousif BM, Fahal AH, Shakir MY. A new technique for the diagnosis of mycetoma using fixed blocks of aspirated material. Trans R Soc Trop Med Hyg. 2010;104(1):6–9. This article in together with the two previous references highlight new diagnostic methods for eumycetoma.PubMedCrossRef
61.
Ahmed AO, Mukhtar MM, Kools-Sijmons M, et al. Development of a species-specific PCR-restriction fragment length polymorphism analysis procedure for identification of Madurella mycetomatis. J Clin Microbiol. 1999;37(10):3175–8.PubMed
62.
Desnos-Ollivier M, Bretagne S, Dromer F, et al. Molecular identification of black-grain mycetoma agents. J Clin Microbiol. 2006;44(10):3517–23.PubMedCrossRef
63.
Czechowski J, Nork M, Haas D, et al. MR and other imaging methods in the investigation of mycetomas. Acta Radiol. 2001;42:24.PubMedCrossRef
64.
Sharif HS, Clark DC, Aabed MY, et al. Mycetoma: comparison of MR imaging with CT. Radiology. 1991;178:865.PubMed
65.
Welsh O, Salinas MC, Rodríguez MA. Treatment of eumycetoma and actinomycetoma. Curr Top Med Mycol. 1995;6:47.PubMed
66.
Mahgoub ES, Gumaa SA. Ketoconazole in the treatment of eumycetoma due to Madurella mycetomii. Trans R Soc Trop Med Hyg. 1984;78:376.PubMedCrossRef
67.
Venugopal PV, Venugopal TV, Ramakrishna ES, Ilavarasi S. Antimycotic susceptibility testing of agents of black grain eumycetoma. J Med Vet Mycol. 1993;31:161.PubMedCrossRef
68.
Smith EL, Kutbi S. Improvement of eumycetoma with itraconazole. J Am Acad Dermatol. 1997;34:279–80.CrossRef
69.
•• Fahal AH, Rahman IA, El-Hassan AM, et al. The safety and efficacy of itraconazole for the treatment of patients with eumycetoma due to Madurella mycetomatis. Trans R Soc Trop Med Hyg. 2011;105(3):127–32. Small prospective study, evaluating the safety and efficacy of itraconazole for the treatment of M. mycetomatis eumycetoma.PubMedCrossRef
70.
71.
•• van Belkum A, Fahal AH, van de Sande WW. In vitro susceptibility of Madurella mycetomatis to posaconazole and terbinafine. Antimicrob Agents Chemother. 2011;55(4):1771–3. First to describe the in vitro susceptibility of M. mycetomatis to posaconazole and terbinafine using 24 clinical isolates.PubMedCrossRef
72.
Negroni R, Tobon A, Bustamante B, et al. Posaconazole treatment of refractory eumycetoma and chromoblastomycosis. Rev Inst Med Trop Sao Paulo. 2005;47(6):339–46.PubMedCrossRef
73.
Difonzo EM, Massi D, Vanzi L, et al. Madurella mycetomatis mycetoma treated successfully with oral posaconazole. J Chemother. 2011;23(4):243–4.PubMed
74.
Lacroix C, De Kerviler E, Morel P, et al. Madurella mycetomatis mycetoma treated successfully with oral voriconazole. Br J Dermatol. 2005;152:1067–8.PubMedCrossRef
75.
Loulergue P, Hot A, Dannaoui E, et al. Successful treatment of black-grain mycetoma with voriconazole. Am J Trop Med Hyg. 2006;75(6):1106–7.PubMed
76.
N'diaye B, Dieng MT, Perez A, et al. Clinical efficacy and safety of oral terbinafine in fungal mycetoma. Int J Dermatol. 2006;45(2):154–7.PubMedCrossRef
77.
•• van de Sande WW, Fahal AH, Bakker-Woudenberg IA, et al. Madurella mycetomatis is not susceptible to the echinocandin class of antifungal agents. Antimicrob Agents Chemother. 2010;54(6):2738–40. Original study showing the lack of in-vitro activity of the echinocandins against M. mycetomatis.PubMedCrossRef
78.
Porte L, Khatibi S, Hajj LE, et al. Scedosporium apiospermum mycetoma with bone involvement successfully treated with voriconazole. Trans R Soc Trop Med Hyg. 2006;100(9):891–4.PubMedCrossRef
79.
McGinnis MR, Pasarell L. In vitro testing of susceptibilities of filamentous ascomycetes to voriconazole, itraconazole, and amphotericin B, with consideration of phylogenetic implications. J Clin Microbiol. 1998;36(8):2353.PubMed
80.
Troke P, Aguirrebengoa K, Arteaga C, et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother. 2008;52(5):1743.PubMedCrossRef
81.
Schaenman JM, DiGiulio DB, Mirels LF, et al. Scedosporium apiospermum soft tissue infection successfully treated with voriconazole: potential pitfalls in the transition from intravenous to oral therapy. J Clin Microbiol. 2005;43(2):973–7.PubMedCrossRef
82.
Matsumoto Y, Oh-I T, Nagai A, et al. Case of cutaneous Scedosporium apiospermum infection successfully treated with voriconazole. J Dermatol. 2009;36(2):98–102.PubMedCrossRef
83.
•• Pappas PG. Sporotrichosis. In: Kauffman CA, Pappas PG, Sobel JD, Dismukes WE, editors. Essentials of clinical mycology. 2nd ed. New York: Springer Press; 2011. p. 387–97. Detailed review on S. schenckii, infection, clinical manifestations, diagnosis and treatment.CrossRef
84.
• López-Romero E, Reyes-Montes MdelR, Pérez-Torres A, et al. Sporothrix schenckii complex and sporotrichosis, an emerging health problem. Future Microbiol. 2011;6(1):85–102. Thorough review of sporotrichosis, with a particular focus of the biology of S. schenkii.PubMedCrossRef
85.
Marimon R, Gené J, Cano J, et al. Molecular phylogeny of Sporothrix schenckii. J Clin Microbiol. 2006;44(9):3251–6.PubMedCrossRef
86.
Marimon R, Cano J, Gené J, et al. Sporothrix brasiliensis, S. globosa, and S. mexicana, three new Sporothrix species of clinical interest. J Clin Microbiol. 2007;45(10):3198–206.PubMedCrossRef
87.
D’Alessio DJ, Leavens LJ, Strumpf GB, Smith CD. An outbreak of sporotrichosis in Vermont associated with sphagnum moss as the source of infection. N Engl J Med. 1965;272:1054–8.CrossRef
88.
Powell KE, Taylor A, Phillips BJ, et al. Cutaneous sporotrichosis in forestry workers: epidemic due to contaminated sphagnum moss. JAMA. 1978;240:232–5.PubMedCrossRef
89.
Centers for Disease Control. Sporotrichosis associated with Wisconsin sphagnum moss. MMWR. 1982;31:542–4.
90.
Itoh M, Okamoto S, Kariya H. Survey of 200 cases of sporotrichosis. Dermatologica. 1986;172:209–13.PubMedCrossRef
91.
Dixon DM, Salkin IF, Duncan RA, et al. Isolation and characterization of Sporothrix schenckii from clinical and environmental sources associated with the largest US epidemic of sporotrichosis. J Clin Microbiol. 1991;29:1106–13.PubMed
92.
Coles FB, Schuchat A, Hibbs JR, et al. A multistate outbreak of sporotrichosis associated with sphagnum moss. Am J Epidemiol. 1992;136:475–87.PubMed
93.
Hajjeh R, McDonnell S, Reef S, et al. Outbreak of sporotrichosis among tree nursery workers. J Infect Dis. 1997;176:499–504.PubMedCrossRef
94.
Dooley DP, Bostic PS, Beckius ML. Spook house sporotrichosis. A point-source outbreak of cutaneous sporotrichosis from hay bale props in a Halloween haunted-house. Arch Intern Med. 1997;157:1885–7.PubMedCrossRef
95.
Barros MB, Schubach AO, Schubach TM, Wanke B, Lambert-Passos SR. An epidemic of sporotrichosis in Rio de Janeiro, Brazil: epidemiological aspects of a series of cases. Epidemiol Infect. 2008;136:1192–6.PubMedCrossRef
96.
Schubach A, Barros MB, Wanke B. Epidemic sporotrichosis. Curr Opin Infect Dis. 2008;21(2):129–33.PubMedCrossRef
97.
•• Madrid IM, Mattei A, Martins A, et al. Feline sporotrichosis in the southern region of rio grande do sul, Brazil: clinical, zoonotic and therapeutic aspects. Zoonoses Public Health. 2010;57(2):151–4. Original article addressing the epidemic of sporotrichosis in Brazil derived from zoonotic transmission of the disease from cats.PubMedCrossRef
98.
• Rees RK, Swartzberg JE. Feline-transmitted sporotrichosis: A case study from California. Dermatol Online J. 2011;17(6):2. Report of zoonotic transmission of sporotrichosis in the United States.PubMed
99.
Pluss JL, Opal SM. Pulmonary sporotrichosis: review of treatment and outcome. Medicine (Baltimore). 1986;65(3):143–53.
100.
Pappas PG, Tellez I, Deep AE, et al. Sporotrichosis in Peru: description of an area of hyperendemicity. Clin Inf Dis. 2000;20:65–70.CrossRef
101.
Fukushiro R. Epidemiology and ecology of sporotrichosis in Japan. Zbl Bakt Hyg A. 1984;257:228–33.
102.
Ramos-e-Silva M, Vasconcelos C, Carneiro S, et al. Sporotrichosis. Clin Dermatol. 2007;25(2):181–7.PubMedCrossRef
103.
Smego Jr RA, Castiglia M, Asperilla MO. Lymphocutaneous syndrome. A review of non-sporothrix causes. Medicine (Baltimore). 1999;78(1):38–63.CrossRef
104.
Mahlberg MJ, Patel R, Rosenman K, et al. Fixed cutaneous sporotrichosis. Dermatol Online J. 2009;15(8):5.PubMed
105.
Kauffman CA. Sporotrichosis. Clin Infect Dis. 1999 Aug;29(2):231–6.
106.
Yacobucci GN, Santilli MD. Sporotrichosis of the knee. A case report. Orthopedics 9:387–90
107.
Yao J, Penn RG, Ray S. Articular sporotrichosis. Clin Orthop. 1986;204:207–14.PubMed
108.
Appenzeller S, Amaral TN, Amstalden EMI, et al. Sporothrix schenckii infection presented as monoarthritis: report of two cases and review of the literature. Clin Rheumatol. 2006;25:926–8.PubMedCrossRef
109.
Chowdhary G, Weinstein A, Klein R, Mascarenhas BR. Sporotrichal arthritis. Ann Rheum Dis. 1991;50:112–4.PubMedCrossRef
110.
Atdjian M, Granda JL, Ingberg HO, et al. Systemic sporotrichosis polytenosynovitis with median and ulnar nerve entrapment. JAMA. 1980;243:1841–2.PubMedCrossRef
111.
Stratton CW, Lichtenstein KA, Lowenstein SR, Phelps DB, Reller LB. Granulomatous tenosynovitis and carpal tunnel syndrome caused by Sporothrix schenckii. Am J Med. 1981;71:161–4.PubMedCrossRef
112.
Schwartz DA. Sporothrix tenosynovitis – differential diagnosis of granulomatous inflammatory disease of the joints. J Rheumatol. 1989;16:550–3.PubMed
113.
Witherspoon CD, Kuhn F, Owens SD, et al. Endophthalmitis due to Sporothrix schenckii after penetrating ocular injury. Ann Ophthalmol. 1990 Oct;22(10):385–8.
114.
Curi AL, Félix S, Azevedo KM, Estrela R, et al. Retinal granuloma caused by Sporothrix schenckii. Am J Ophthalmol. 2003;136(1):205–7.PubMedCrossRef
115.
Schubach A, de Lima Barros MB, Schubach TM, et al. Primary conjunctival sporotrichosis: two cases from a zoonotic epidemic in Rio de Janeiro, Brazil. Cornea. 2005;24(4):491–3. Review.PubMedCrossRef
116.
Kashima T, Honma R, Kishi S, et al. Bulbar conjunctival sporotrichosis presenting as a salmon-pink tumor. Cornea. 2010;29(5):573–6.PubMedCrossRef
117.
Iyengar SS, Khan JA, Brusco M, et al. Cutaneous Sporothrix schenckii of the human eyelid. Ophthal Plast Reconstr Surg. 2010;26(4):305–6.PubMedCrossRef
118.
Heller HM, Fuhrer J. Disseminated sporotrichosis in patients with AIDS: case report and review of the literature. AIDS. 1991 Oct;5(10):1243–6.
119.
al-Tawfiq JA, Wools KK. Disseminated sporotrichosis and Sporothrix schenckii fungemia as the initial presentation of human immunodeficiency virus infection. Clin Infect Dis. 1998;26(6):1403–6.PubMedCrossRef
120.
Yelverton CB, Stetson CL, Bang RH, et al. Fatal sporotrichosis. Cutis. 2006 Oct;78(4):253–6.
121.
Zhang YQ, Xu XG, Zhang M, et al. Sporotrichosis: clinical and histopathological manifestations. Am J Dermatopathol. 2011;33(3):296–302.PubMedCrossRef
122.
•• Assi M, Lakkis IE, Wheat LJ. Cross-reactivity in the Histoplasma antigen enzyme immunoassay caused by sporotrichosis. Clin Vaccine Immunol. 2011;18(10):1781–2. Report of a case of false positive Histoplasma antigen enzyme immunoassay in a patient with pulmonary sporotrichosis.PubMedCrossRef
123.
Kauffman CA, Bustamante B, Chapman SW, et al. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis. 2007;45(10):1255–65.PubMedCrossRef
124.
Restrepo A, Robledo J, Gomez I, Tabares AM, Gutierrez R. Itraconazole therapy in lymphangitic and cutaneous sporotrichosis. Arch Dermatol. 1986;122:413–7.PubMedCrossRef
125.
Conti Diaz IA, Civila E, Gezuele E, et al. Treatment of human cutaneous sporotrichosis with itraconazole. Mycoses. 1992;35:153–6.PubMedCrossRef
126.
Sharkey-Mathis PK, Kauffman CA, Graybill JR, et al. Treatment of sporotrichosis with itraconazole. NIAID Mycoses Study Group. Am J Med. 1993;95:279–85.PubMedCrossRef
127.
•• de Lima Barros MB, Schubach AO, de Vasconcellos Carvalhaes de Oliveira R, et al. Treatment of cutaneous sporotrichosis with itraconazole–study of 645 patients. Clin Infect Dis. 2011;52(12):e200–6. Large prospective study evaluating the safety and efficacy of itraconazole, most of the patients in the study received itraconazole 100 mg daily with excellent results.CrossRef
128.
•• Song Y, Zhong SX, Yao L, et al. Efficacy and safety of itraconazole pulses vs. continuous regimen in cutaneous sporotrichosis. J Eur Acad Dermatol Venereol. 2011;25(3):302–5. Small-randomized trial comparing itraconazole pulses vs. continuous regimen in cutaneous sporotrichosis.PubMedCrossRef
129.
Chapman SW, Pappas P, Kauffman C, et al. Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1000 mg day) in the treatment of cutaneous or lymphocutaneous sporotrichosis. Mycoses. 2004;47:62–8.PubMedCrossRef
130.
•• Yamada K, Zaitz C, Framil VM, et al. Cutaneous sporotrichosis treatment with potassium iodide: a 24 year experience in São Paulo State, Brazil. Rev Inst Med Trop Sao Paulo. 2011;53(2):89–93. A retrospective analysis evaluating the safety and efficacy of potassium iodine in the treatment of cutaneous sporotrichosis.PubMed
131.
•• Xue S, Gu R, Wu T, et al. Oral potassium iodide for the treatment of sporotrichosis. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD006136. A cochrane review of the evidence of potassium iodine for the treatment of sporotrichosis.
132.
Francesconi G, Valle AC, Passos S, et al. Terbinafine (250 mg/day): an effective and safe treatment of cutaneous sporotrichosis. J Eur Acad Dermatol Venereol. 2009;23(11):1273–6.PubMedCrossRef
133.
•• Francesconi G, Francesconi do Valle AC, et al. Comparative study of 250 mg/day terbinafine and 100 mg/day itraconazole for the treatment of cutaneous sporotrichosis. Mycopathologia. 2011;171(5):349–54. This study combined with the prior reference suggest that terbinafine 250 mg is an effective option for the treatment of sporotrichosis.PubMedCrossRef
134.
McGinnis MR, Nordoff N, Li RK, et al. Sporothrix schenckii sensitivity to voriconazole, itraconazole and amphotericin B. Med Mycol. 2001;39(4):369–71.PubMed
Metadata
Title
Subcutaneous Fungal Infections
Authors
Ricardo M. La Hoz
John W. Baddley
Publication date
01-10-2012
Publisher
Current Science Inc.
Published in
Current Infectious Disease Reports / Issue 5/2012
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-012-0275-3

Other articles of this Issue 5/2012

Current Infectious Disease Reports 5/2012 Go to the issue

Sepsis (J Russell, Section Editor)

Variability Analysis and the Diagnosis, Management, and Treatment of Sepsis

Skin, Soft Tissue, Bone and Joint Infections (N Safdar, Section Editor)

From Ulcer to Infection: An Update on Clinical Practice and Adjunctive Treatments of Diabetic Foot Ulcers

Skin, Soft Tissue, Bone and Joint Infections (N Safdar, Section Editor)

Chronic Osteomyelitis

Skin, Soft Tissue, Bone, and Joint Infections (N Safdar, Section Editor)

Prosthetic Joint Infections

Sepsis (J Russell, Section Editor)

Cardiovascular Management of Septic Shock in 2012

Sepsis (J Russell, Section Editor)

Toll-Like Receptors and Opportunities for New Sepsis Therapeutics
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits